# Clinical Pharmacology of Efavirenz Combined with High Dose Rifapentine

> **NIH NIH K23** · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2022 · $162,603

## Abstract

Project Summary
Dr. Anthony Podany is applying for a patient oriented career development award (NIH-K23) for training in
clinical trial design and implementation and training the in techniques of pharmacokinetic modeling and
pharmacometrics. As part of the award, he plans to complete a Masters degree in pharmacometrics at the
University of Maryland. This training builds upon Dr. Podany’s previous training in infectious disease
pharmacology.
The members of Dr. Podany’s mentoring team are Drs. Courtney V. Fletcher, Richard E. Chaisson, Susan
Swindells, and Kim Scarsi, all internationally recognized leaders in HIV and tuberculosis research. Dr.
Courtney V. Fletcher will serve as Dr. Podany’s primary mentor and will facilitate continued training in HIV and
TB pharmacology, and in responsible conduct of research. Dr. Podany will also complete other didactic
training in responsible conduct of research in the classroom through the Collaborative Institutional Training
Initiative (CITI) and Clinical Research Symposium for junior faculty at the University of Nebraska Medical
Center.
Training in pharmacokinetic modeling will be achieved though didactic coursework from the University of
Maryland, with practical training under Dr. Richard Brundage, who is an expert in pharmacokinetic modeling.
His instruction will be an essential component of Dr. Podany’s training.
Data from Dr. Podany’s research will help bring about novel therapeutic options for the treatment of latent and
active tuberculosis disease in patients who are also infected with HIV. Data from this research will inform the
field and guide updates for guidelines on the treatment of HIV/TB co-infected patients. The project is of high
human health relevance.
On completion of the award period, Dr. Podany will have the expertise to conduct independent research in HIV
and tuberculosis pharmacology. He will have completed in-depth training in pharmacokinetic modeling and
clinical and translational research, allowing him to become a leader in the field of HIV and tuberculosis
pharmacology.

## Key facts

- **NIH application ID:** 10385802
- **Project number:** 5K23AI134307-05
- **Recipient organization:** UNIVERSITY OF NEBRASKA MEDICAL CENTER
- **Principal Investigator:** ANTHONY T PODANY
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $162,603
- **Award type:** 5
- **Project period:** 2018-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10385802

## Citation

> US National Institutes of Health, RePORTER application 10385802, Clinical Pharmacology of Efavirenz Combined with High Dose Rifapentine (5K23AI134307-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10385802. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*